Auxilium Pharmaceuticals, Inc.
) jumped 11.95% with the FDA approving Xiaflex for an additional
indication. Xiaflex, which is currently marketed for Dupuytren's
Contracture, gained approval for Peyronie's disease.
FDA approval makes Xiaflex the first and only treatment
approved by the agency that is considered effective for
Peyronie's disease in men with a palpable plaque and a curvature
deformity of 30 degrees or greater at the start of therapy. With
Peyronie's disease patients having little other option besides
surgery, Xiaflex should be a welcome alternative for Peyronie's
According to data provided by Auxilium Pharma, about 65,000 -
120,000 Peyronie's disease patients are diagnosed every year.
However, only 5,000 to 6,500 Peyronie's disease patients go for
treatment with injectables or surgery.
Although the approval comes with a Boxed warning in the label
and a risk evaluation and mitigation strategy (REMS) program,
this should not affect uptake of the product.
We are impressed with Auxilium Pharma's efforts to lower its
dependence on Testim. The Actient acquisition earlier this year,
the full promotional launch of Stendra in January, and now the
approval of Xiaflex for Peyronie's will help strengthen the
company's position in the men's healthcare area.
Xiaflex, in-licensed from
BioSpecifics Technologies Corp.
), is being studied for additional indications as well including
for the treatment of cellulite and frozen shoulder syndrome.
Shares of BioSpecifics Technologies were up 6.5% on the label
expansion for Xiaflex into the Peyronie's indication.
Auxilium Pharma currently carries a Zacks Rank #2 (Buy). Some
better-ranked stocks in the same sector include BioSpecifics
Questcor Pharmaceuticals, Inc.
). All are Zacks Rank #1 (Strong Buy) stocks.
AUXILIUM PHARMA (AUXL): Free Stock Analysis
BIOSPECIFICS TE (BSTC): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.